Journal article
Pharmacological Inhibition of Factor XIIa Attenuates Abdominal Aortic Aneurysm, Reduces Atherosclerosis, and Stabilizes Atherosclerotic Plaques
AK Searle, YC Chen, M Wallert, JD McFadyen, AC Maluenda, J Noonan, P Kanellakis, MTK Zaldivia, A Huang, H Lioe, M Biondo, MW Nolte, P Rossato, A Bobik, C Panousis, X Wang, H Hosseini, K Peter
Thrombosis and Haemostasis | GEORG THIEME VERLAG KG | Published : 2022
DOI: 10.1055/a-1663-8208
Abstract
Background 3F7 is a monoclonal antibody targeting the enzymatic pocket of activated factor XII (FXIIa), thereby inhibiting its catalytic activity. Given the emerging role of FXIIa in promoting thromboinflammation, along with its apparent redundancy for hemostasis, the selective inhibition of FXIIa represents a novel and highly attractive approach targeting pathogenic processes that cause thromboinflammation-driven cardiovascular diseases. Methods The effects of FXIIa inhibition were investigated using three distinct mouse models of cardiovascular disease-angiotensin II-induced abdominal aortic aneurysm (AAA), an ApoE_/_ model of atherosclerosis, and a tandem stenosis model of atherosclerotic..
View full abstractGrants
Funding Acknowledgements
This work was supported by the National Heart Foundation of Australia for A.K.S., Y.-C.C., J.D.M., and X.W.; by the German Research Foundation for M.W.; and by the National Health and Medical Research Council for J.D.M. and K.P. CSL Limited supported this research with an unrestricted research fund.